Meeting
2022 ASCO Genitourinary Cancers Symposium
Evaluating a polygenic hazard score to predict risk of developing metastatic or fatal prostate cancer in the multi-ancestry Million Veteran Program cohort.
Authors
Meghana Pagadala
VA San Diego Healthcare System, La Jolla, CA
Meghana Pagadala , Julie Ann Lynch , Roshan Karunamuni , Patrick Alba , Kyung Min Lee , Fatai Agiri , Tori Anglin-Foote , Hannah Carter , J. Michael Gaziano , Guneet Kaur Jasuja , Rishi Deka , Brent S. Rose , Matthew Panizzon , Richard Hauger , Tyler Seibert
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Translational Research, Tumor Biology, Biomarkers, and Pathology
Citation
J Clin Oncol 40, 2022 (suppl 6; abstr 155)
DOI
10.1200/JCO.2022.40.6_suppl.155
Abstract #
155
Poster Bd #
H11
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Genitourinary Cancers Symposium
Healthy lifestyle, Agent Orange exposure, and inherited PCa risk: An analysis of the Million Veteran Program.
First Author: Meghana Pagadala
Poster
2020 ASCO Virtual Scientific Program
Association of polymorphisms in androgen production, uptake, and conversion chain (APUC) genes with mortality of prostate cancer patients.
First Author: Sean Thomas McSweeney
Poster
2016 ASCO Quality Care Symposium
Choosing Wisely in oncology: Screening for a new primary cancer in patients with metastatic disease.
First Author: Simron Singh
Poster
2024 ASCO Genitourinary Cancers Symposium
Men with adrenal-permissive HSD3B1 genotype and prostate cancer mortality: Results from the Veterans Affairs Health System Million Veteran Program.
First Author: Rana R. McKay